Today we unveiled a multiphase partnership with Novelty Nobility Inc., a clinical-stage biotech company based in South Korea. Novelty Nobility will leverage AGC Biologics’ expertise and proprietary CHEF1® expression technology for cell line development and prepare for Phase I clinical trials via a multi-site partnership with AGC Biologics’ Copenhagen, Denmark and Chiba, Japan facilities.

今天我们宣布与总部位于韩国的临床阶段生物技术公司Novelty Nobility Inc.达成多阶段合作伙伴关系。Novelty Nobility将利用AGC Biologics的专业知识及其专有的CHEF1®表达技术进行细胞系开发，并通过与AGC Biologics位于丹麦哥本哈根和日本千叶的设施合作，为第一阶段临床试验做准备。

.

。

Novelty Nobility develops innovative antibody drugs, including bispecific antibodies and antibody-drug conjugates (ADCs). The company is currently developing two clinical assets in the United States in immunology and oncology, respectively.

创新贵族公司开发创新的抗体药物，包括双特异性抗体和抗体-药物偶联物（ADC）。该公司目前正在美国开发两种分别针对免疫学和肿瘤学的临床资产。

AGC Biologics will develop the cell line and create a master cell bank (MCB) for Novelty Nobility’s first-in-class bispecific antibody drug candidate at its Copenhagen facility. After the MCB is created, the second phase of the partnership will focus on expanded process development work and GMP manufacturing preparation at the AGC Biologics Chiba site.

AGC生物制品公司将在其哥本哈根工厂为Novelty Nobility的首创新型双特异性抗体候选药物开发细胞系并创建主细胞库（MCB）。主细胞库创建完成后，合作的第二阶段将集中在AGC生物制品公司千叶基地的扩展工艺开发工作和GMP生产准备上。

The first stage of the project began in March..

项目的第一阶段于三月开始。

'We are very happy with the partnership with Novelty Nobility, where we will apply our CHEF1 platform to a novel bispecific antibody, helping support the advancement of this important candidate towards clinical trials,' said Kasper Møller, Chief Technical Officer and Executive Vice President, AGC Biologics.

“我们对与 Novelty Nobility 的合作感到非常高兴，我们将把我们的 CHEF1 平台应用于一种新型双特异性抗体，帮助推动这一重要候选药物向临床试验迈进，”AGC Biologics 首席技术官兼执行副总裁 Kasper Møller 表示。

'Our cell line development expertise in Copenhagen is strategically aligned with Novelty Nobility's objectives, and we believe we can provide a strong foundation for their therapeutic development program.' .

“我们在哥本哈根的细胞系开发专业知识与 Novelty Nobility 的目标高度契合，我们相信可以为他们的治疗开发计划提供坚实的基础。”

'Chiba's partnership with our Copenhagen team gives Novelty Nobility access to world-class cell line development experts while keeping their regional connection strong,' noted Susumu Zen-in, Senior Vice President and General Manager, AGC Biologics Chiba. 'When clients work with us, they tap into our entire global network – we find the right expertise wherever it exists and bring teams together for a seamless experience, no matter where the work is being done.

千叶与哥本哈根团队的合作使新奇贵族能够接触到世界级的细胞系开发专家，同时保持其区域联系的紧密。” AGC Biologics千叶公司的高级副总裁兼总经理善忍禅院指出，“当客户与我们合作时，他们可以利用我们的整个全球网络——无论工作在何处进行，我们都能找到合适的专业知识，并将团队聚集在一起，提供无缝体验。"

This approach is already helping us throughout the APAC region and creating wins for both Novelty Nobility and AGC Biologics.' .

这种方法已经在整个亚太地区帮助了我们，并为新奇贵族公司和AGC生物制品公司创造了双赢。

AGC Biologics' CHEF1 expression technology is a proven platform for cell line development, with a track record of producing stable cell lines for a variety of biologics. With five commercial products on the market and 54 distinct molecules developed, the platform delivers a reliable and efficient path to success.

AGC Biologics的CHEF1表达技术是一个经过验证的细胞系开发平台，拥有为多种生物制品生产稳定细胞系的成功记录。凭借市场上已有五个商业化产品和54种不同分子的开发经验，该平台提供了一条可靠且高效的致胜之路。

The cell line platform excels in handling complex molecules, providing solutions for challenging biologics that require specialized expression systems. The CHEF1 platform is also royalty-free, eliminating additional costs for clients as their products advance through clinical phases toward commercialization. .

该细胞系平台擅长处理复杂分子，为需要专门表达系统的具有挑战性的生物制品提供解决方案。CHEF1 平台还免收专利费，消除了客户产品在通过临床阶段迈向商业化过程中产生的额外成本。

AGC Biologics offers a comprehensive suite of services for mammalian-based drug production, from cell line development to commercial manufacturing, enabling partners to accelerate their drug development timelines and bring life-changing therapies to patients. Visit www.agcbio.com/capabilities/mammalian to learn more.

AGC Biologics 提供从细胞系开发到商业化生产的全面哺乳动物基药物生产服务，帮助合作伙伴加速药物开发进程，为患者带来改变生命的疗法。访问 www.agcbio.com/capabilities/mammalian 了解更多信息。

.

。

Source: agcbio.com

来源：agcbio.com